BioCentury
ARTICLE | Financial News

Consonance, Jay Mohr partner to invest in deprioritized therapeutics

May 25, 2018 6:20 PM UTC

Through a collaboration with biotech executive Jay Mohr, Consonance Capital Partners (New York, N.Y.) plans to make its first therapeutics investments out of its $500 million private equity fund, with the aim of increasing the profitability of deprioritized marketed drugs.

Mohr is President and CEO of Dirigo Therapeutics LLC, which he launched in 2016 to acquire and commercialize products the company believes have underperformed. He previously held executive positions at biotechs including cancer company Gloucester Pharmaceuticals Inc. and diagnostics company Variagenics Inc., and founded life sciences consultancy Locust Walk Partners in 2008...